By: Christina Bennett, MS From: cancertherapyadvisor.com Locoregional treatment was found to improve survival for patients with de novo stage IV breast cancer and bone-only metastasis, according to the results of a multicenter registry study reported at the 17th St. Gallen International Breast Cancer Conference 2021. BOMET MF14-01 (ClinicalTrials.gov Identifier: NCT02125630) included 505 patients with de novo stage IV breast cancer …
Intravenous Cetirizine Prevents Infusion Reactions From Paclitaxel in Breast Cancer, Other Tumors
By: Gina Mauro From: onclive.com Intravenous cetirizine showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions in patients with cancer who are undergoing treatment with an anti-CD20 antibody or paclitaxel. Intravenous (IV) cetirizine (Quzyttir) showed comparable efficacy to IV diphenhydramine for the prevention of infusion reactions (IRs) in patients with cancer who are undergoing treatment with an …
Less Diarrhea Seen When Neratinib Given in Dose-Escalated Fashion for Breast Cancer
By: Christina Bennett, MS From: cancertherapyadvisor.com Administering neratinib in a dose-escalated fashion with optional loperamide was found to reduce the incidence of severe diarrhea in patients with HER2-positive, early-stage breast cancer, according to data from the phase 2 CONTROL trial reported at the 17th St. Gallen International Breast Cancer Conference 2021. The CONTROL trial (ClinicalTrials.gov Identifier: NCT02400476) enrolled 563 patients …
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen
From: businesswire.com – Trial will evaluate the efficacy and safety of Novartis’ targeted therapy TABRECTA® and Puma’s NERLYNX® in patients with metastatic HER2-negative breast cancer selected by Celcuity’s CELsignia Multi-Pathway Activity Test – This is Celcuity’s second clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies – Five clinical trial collaborations …
BDC-1001 +/- Immune Checkpoint Inhibitor Therapy Under Investigation for HER2+ Breast Cancer
By: Sara Karlovitch From: targetedonc.com Currently, the only immune-based therapy for patients with HER2-driven or expressing cancers are anti-HER2 monoclonal antibodies. More treatment options are needed for patients who develop progressive disease. A trail in progress presented at the virtual 2020 San Antonio Breast Cancer Symposium suggests that immunostimulatory adjuvants such as toll-like receptor (TLR) 7/8 can help cause T-cells …
CONTESSA Trial Yields Positive Results for Patients with HER2-Positive Breast Cancer
By: Sara Karlovitch From: targetedonc.com In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA study of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer. New data suggests that a …
Allarity Therapeutics Begins European Study of Ixempra for Biomarker-Selected Breast Cancer Patients
By: Staff Reporter From: precisiononcologynews.com Allarity Therapeutics on Thursday said that it has enrolled the first patient in a European Phase II clinical trial evaluating the microtubulin inhibitor ixabepilone (Ixempra) as a third-line treatment for certain metastatic breast cancers. Specifically, Allarity — previously named Oncology Venture — will evaluate the agent, a product for which it in-licensed the European rights …
PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer
By: Matthew Fowler From: cancernetwork.com The PHERGain II trial will investigate the treatment of patients with early HER2-positive breast cancer using a chemotherapy-free treatment approach of trastuzumab plus pertuzumab. A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is as effective as the current standard of …
Phase 3 OlympiA Trial for HER2-Negative Breast Cancer Moves to Early Primary Analysis Per IDMC Recommendation
By: Hannah Slater From: cancernetwork.com In the OlympiA trial, patients with high-risk HER2-negative breast cancer were randomized 1:1 to receive either olaparib or placebo for 12 months. A planned interim analysis found that the phase 3 OlympiA trial (NCT02032823) crossed the superiority boundary for its primary end point of invasive disease-free survival (iDFS) and demonstrated a sustainable, clinically relevant treatment …
Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE)
From: thelancet.com A multicentre, open-label, randomised, controlled, phase 3 trial Background Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine after previous trastuzumab. Methods This is an open-label, randomised, controlled, phase 3 trial done at 29 …